OBESITY MANAGEMENT - A COMPARATIVE REVIEW OF THE EFFICACY AND SAFETY OF BARIATRIC SURGERY AND TIRZEPATIDE THERAPY
Abstract
Objective: Obesity is a major global health burden associated with increased morbidity, mortality, and healthcare costs. This review aimed to compare the efficacy and safety of tirzepatide, a novel dual GLP-1/GIP receptor agonist, with bariatric surgery, focusing on their roles in weight reduction, metabolic improvement, and long-term risk–benefit profiles.
Methods: A comprehensive literature search was performed using PubMed and official regulatory and professional society sources (FDA, EMA, MHRA, IFSO). Search terms included “obesity,” “bariatric surgery,” “tirzepatide,” and “GLP-1 and GIP receptor agonist.” Only peer-reviewed English-language studies with high levels of evidence, including randomized controlled trials, meta-analyses, systematic reviews, and clinical guidelines, were included.
Key Findings: Bariatric surgery, particularly Roux-en-Y gastric bypass and sleeve gastrectomy, was associated with the most profound and durable weight loss (25–28% short-term; 18–25% long-term), alongside significant remission of type 2 diabetes, hypertension, and dyslipidemia. However, its invasive nature and risk of perioperative and late complications necessitate multidisciplinary follow-up. Tirzepatide demonstrated dose-dependent reductions in body weight (~10–20%), improved glycemic control, lipid profiles, and blood pressure, and enhanced quality of life. Its safety profile was favorable, predominantly gastrointestinal, but long-term data remain limited.
Conclusions: Bariatric surgery remains the gold standard for severe obesity due to its magnitude and sustainability of benefits. Tirzepatide represents a promising, less-invasive pharmacological option, particularly for patients with moderate obesity or contraindications to surgery. Further research is required to establish its long-term efficacy and safety profile.
References
Faccioli, N., Poitou, C., Clément, K., & Dubern, B. (2023). Current treatments for patients with genetic obesity. Journal of Clinical Research in Pediatric Endocrinology, 15(2), 108–119. https://doi.org/10.4274/jcrpe.galenos.2023.2023-3-2
Masood, B., & Moorthy, M. (2023). Causes of obesity: A review. Clinical Medicine, 23(4), 284–291. https://doi.org/10.7861/clinmed.2023-0168
Brown, A., & Ravi, B. (2022). As the prevalence of obesity increases, rationing arthritis care is not the answer. Osteoarthritis and Cartilage, 30(9), 1157–1158. https://doi.org/10.1016/j.joca.2022.06.007
Weir, C. B., & Jan, A. (2023). BMI classification percentile and cut off points. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK541070/
Mayoral, L. P., Andrade, G. M., Mayoral, E. P., Huerta, T. H., Canseco, S. P., Rodal Canales, F. J., Cabrera-Fuentes, H. A., Cruz, M. M., Pérez Santiago, A. D., Alpuche, J. J., Zenteno, E., Ruíz, H. M., Cruz, R. M., Jeronimo, J. H., & Perez-Campos, E. (2020). Obesity subtypes, related biomarkers & heterogeneity. Indian Journal of Medical Research, 151(1), 11–21. https://doi.org/10.4103/ijmr.IJMR_1768_17
Fulton, S., Décarie-Spain, L., Fioramonti, X., Guiard, B., & Nakajima, S. (2022). The menace of obesity to depression and anxiety prevalence. Trends in Endocrinology & Metabolism, 33(1), 18–35. https://doi.org/10.1016/j.tem.2021.10.005
Okunogbe, A., Nugent, R., Spencer, G., Powis, J., Ralston, J., & Wilding, J. (2022). Economic impacts of overweight and obesity: Current and future estimates for 161 countries. BMJ Global Health, 7(9), e009773. https://doi.org/10.1136/bmjgh-2022-009773
Hachuła, M., Kosowski, M., Zielańska, K., Basiak, M., & Okopień, B. (2023). The impact of various methods of obesity treatment on the quality of life and mental health: A narrative review. International Journal of Environmental Research and Public Health, 20(3), 2122. https://doi.org/10.3390/ijerph20032122
Hamza, M., Papamargaritis, D., & Davies, M. J. (2025). Tirzepatide for overweight and obesity management. Expert Opinion on Pharmacotherapy, 26(1), 31–49. https://doi.org/10.1080/14656566.2024.2436595
Aderinto, N., Olatunji, G., Kokori, E., Olaniyi, P., Isarinade, T., & Yusuf, I. A. (2023). Recent advances in bariatric surgery: A narrative review of weight loss procedures. Annals of Medicine and Surgery, 85(12), 6091–6104. https://doi.org/10.1097/MS9.0000000000001472
Askari, A., Jambulingam, P., Gurprashad, R., Al-Taan, O., Adil, T., Munasinghe, A., Jain, V., Rashid, F., & Whitelaw, D. (2023). The surgical management of obesity. Clinical Medicine, 23(4), 330–336. https://doi.org/10.7861/clinmed.2023-0189
Mitchell, B. G., Collier, S. A., & Gupta, N. (2024). Roux-en-Y gastric bypass. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK542311/
Angrisani, L., Santonicola, A., Iovino, P., Palma, R., Kow, L., Prager, G., Ramos, A., & Shikora, S.; Collaborative Study Group for the IFSO Worldwide Survey. (2024). IFSO worldwide survey 2020–2021: Current trends for bariatric and metabolic procedures. Obesity Surgery, 34(4), 1075–1085. https://doi.org/10.1007/s11695-024-07118-3
Di Lorenzo, N., Antoniou, S. A., Batterham, R. L., Busetto, L., Godoroja, D., Iossa, A., Carrano, F. M., … Silecchia, G. (2020). Clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) on bariatric surgery: Update 2020 endorsed by IFSO-EC, EASO and ESPCOP. Surgical Endoscopy, 34(6), 2332–2358. https://doi.org/10.1007/s00464-020-07555-y
Ram Sohan, P., Mahakalkar, C., Kshirsagar, S., Bikkumalla, S., Reddy, S., Hatewar, A., & Dixit, S. (2024). Long-term effectiveness and outcomes of bariatric surgery: A comprehensive review of current evidence and emerging trends. Cureus, 16(8), e66500. https://doi.org/10.7759/cureus.66500
Kim, J. C., Kim, M. G., Park, J. K., Lee, S., Kim, J., Cho, Y. S., Kong, S. H., Park, D. J., Lee, H. J., & Yang, H. K. (2023). Outcomes and adverse events after bariatric surgery: An updated systematic review and meta-analysis, 2013–2023. Journal of Metabolic and Bariatric Surgery, 12(2), 76–88. https://doi.org/10.17476/jmbs.2023.12.2.76
Raza, M. M., Njideaka-Kevin, T., Polo, J., & Azimuddin, K. (2023). Long-term outcomes of bariatric surgery: A systematic review. Cureus, 15(5), e39638. https://doi.org/10.7759/cureus.39638
Law, S., Dong, S., Zhou, F., Zheng, D., Wang, C., & Dong, Z. (2023). Bariatric surgery and mental health outcomes: An umbrella review. Frontiers in Endocrinology, 14, 1283621. https://doi.org/10.3389/fendo.2023.1283621
Loh, H. H., Francis, B., Lim, L. L., Lim, Q. H., Yee, A., & Loh, H. S. (2021). Improvement in mood symptoms after post-bariatric surgery among people with obesity: A systematic review and meta-analysis. Diabetes/Metabolism Research and Reviews, 37(8), e3458. https://doi.org/10.1002/dmrr.3458
Goel, R., Nasta, A. M., Goel, M., Prasad, A., Jammu, G., Fobi, M., … Bhandari, M. (2021). Complications after bariatric surgery: A multicentric study of 11,568 patients from Indian bariatric surgery outcomes reporting group. Journal of Minimal Access Surgery, 17(2), 213–220. https://doi.org/10.4103/jmas.JMAS_12_20
Tsenteradze, T., Fayyaz, F., Ekhator, C., Ahmed, I., Oliveira Souza Lima, S. R., Daher, O. A., Bakht, D., … Hussain, A. (2023). Navigating bariatric surgery: Understanding and managing short-term and long-term complications. Cureus, 15(11), e48580. https://doi.org/10.7759/cureus.48580
Francois, Z., & Rizvi, A. (2024). Psychiatric complications of bariatric surgery. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK597228/
National Institute of Diabetes and Digestive and Kidney Diseases. (2012–). LiverTox: Clinical and research information on drug-induced liver injury. National Institutes of Health. https://www.ncbi.nlm.nih.gov/books/NBK548270/
Willard, F. S., Douros, J. D., Gabe, M. B., Showalter, A. D., Wainscott, D. B., Suter, T. M., … Sloop, K. W. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17), e140532. https://doi.org/10.1172/jci.insight.140532
U.S. Food and Drug Administration. (2025, May 24). FDA approves new medication for chronic weight management. Retrieved May 24, 2025, from https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
European Medicines Agency. (2025, May 24). Mounjaro: European public assessment report (EPAR). Retrieved May 24, 2025, from https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro
Medicines and Healthcare products Regulatory Agency. (2025, May 24). MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss. Retrieved May 24, 2025, from https://www.gov.uk/government/news/mhra-authorises-diabetes-drug-mounjaro-tirzepatide-for-weight-management-and-weight-loss
Cai, W., Zhang, R., Yao, Y., Wu, Q., & Zhang, J. (2024). Tirzepatide as a novel effective and safe strategy for treating obesity: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Public Health, 12, 1277113. https://doi.org/10.3389/fpubh.2024.1277113
Qin, W., Yang, J., Ni, Y., Deng, C., Ruan, Q., Ruan, J., Zhou, P., & Duan, K. (2024). Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial. Endocrine, 86(1), 70–84. https://doi.org/10.1007/s12020-024-03896-z
Marie Gibble, T., Cao, D., Murphy, M., Jouravskaya, I., & Liao, B. (2024). Tirzepatide improved mental and psychosocial health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-4 phase 3 trial. Journal of the Endocrine Society, 8(Suppl 1), bvae163.043. https://doi.org/10.1210/jendso/bvae163.043
Farzam, K., & Patel, P. (2024). Tirzepatide. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/sites/books/NBK585056/
Al Zweihary, A. M. (2024). Safety and effectiveness of tirzepatide use in obesity without type 2 diabetes mellitus. Cureus, 16(1), e51788. https://doi.org/10.7759/cureus.51788
Views:
39
Downloads:
13
Copyright (c) 2025 Wojciech Gąska, Ignacy Rożek, Izabela Lekan, Joanna Mazurek, Agnieszka Brzezińska, Weronika Tuszyńska, Alicja Sodolska, Michał Lenart, Barbara Madoń, Barbara Teresińska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
